Assort Health, a healthcare AI agent startup, announced a $120 million Series C on June 24, 2026, led by Menlo Ventures. The round values the company at $1.2 billion and brings its total funding to more than $222 million since it launched in November 2023, according to the company's announcement and PR Newswire filing.
Lightspeed Venture Partners, Felicis, First Round Capital, Chemistry, Tau Ventures, Quiet Capital and investor Joe Montana also participated. Several of these firms, including Lightspeed, First Round Capital, Felicis and Chemistry, backed Assort's $76 million Series B just eight months earlier, in September 2025.
What Assort Health does
Assort builds specialty-specific AI voice agents that handle tasks across what the company calls the patient journey: appointment scheduling, intake forms, referral processing, document handling, medication refills, real-time insurance eligibility checks, lab requests and payments. The agents are built for individual specialties, including orthopedics, cardiology and immunology, rather than as a single generic call-handling tool.
The company says its platform is trained on a dataset built from 190 million patient interactions, 62,000 care protocols and 1.6 million decision pathways, according to its funding announcement. TechShorts has not independently verified these figures and reports them as stated by the company.
Assort has focused first on specialty practices, where scheduling and intake are more complex than in primary care, and is now expanding into large health systems. John Muir Health is named in the company's announcement as one health system now partnering with Assort as it moves into more complex, large-scale ambulatory operations.
Who is affected
The immediate audience is healthcare provider organizations, particularly specialty practice groups and health systems evaluating AI tools for front-office and patient access operations. Assort's expansion into health systems signals a shift from serving individual specialty clinics toward larger, more complex provider networks with higher transaction volume and more integration requirements.
Competing vendors in the patient access and voice AI space are also affected. Founder and co-CEO Jon Wang framed the raise as a bet on consolidation: "This market is going to consolidate in the same way every other one has. Provider groups know it, and the smart ones aren't buying another point solution. They want one partner with the capital and the engineering depth to transform how they operate over the long run," Wang said in the company's announcement.
Wang also tied the new capital directly to product development, saying: "Our engineers learn across hundreds of customers and build every implementation for the specific practice in front of them, and we have now raised over $220M to make that engine better."
What affected parties should know
The Series C arrived roughly eight months after Assort's Series B, a pace that reflects how fast healthcare AI funding has moved in 2026 rather than any specific operational milestone disclosed alongside the raise. The company has not published third-party validated outcome data, such as independently audited reductions in no-show rates or call abandonment, alongside this funding announcement. Provider organizations evaluating the platform should treat the company's own performance descriptions, including the size and composition of its training dataset, as vendor-stated claims rather than independently confirmed figures.
Assort's move upmarket into health systems also means its product will need to integrate with a wider range of electronic health record and practice management systems than the specialty-clinic deployments it has focused on so far. Neither the company's announcement nor the coverage of the raise details specific EHR integration partnerships tied to the new funding.
What happens next
Assort says the new capital will fund continued scaling of what it calls the largest deployment of AI agents across the patient journey, along with further health system partnerships beyond John Muir Health. The company has not disclosed a specific timeline for additional health system agreements or a public roadmap for new specialty coverage.
Whether Assort's consolidation thesis plays out will depend on how many additional health systems sign on and whether competing point solutions get absorbed or squeezed out, neither of which is yet confirmed by any source as of this writing.
Sources: Assort Health · PR Newswire · MobiHealthNews · Fierce Healthcare · Fierce Healthcare Series B · Fortune